Coloplast Balance Sheet Health

Financial Health criteria checks 2/6

Coloplast has a total shareholder equity of DKK17.9B and total debt of DKK21.6B, which brings its debt-to-equity ratio to 120.6%. Its total assets and total liabilities are DKK48.1B and DKK30.1B respectively. Coloplast's EBIT is DKK7.3B making its interest coverage ratio 11.4. It has cash and short-term investments of DKK788.0M.

Key information

120.6%

Debt to equity ratio

DKK 21.64b

Debt

Interest coverage ratio11.4x
CashDKK 788.00m
EquityDKK 17.94b
Total liabilitiesDKK 30.13b
Total assetsDKK 48.07b

Recent financial health updates

Recent updates

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Dec 04
Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Should Shareholders Have Second Thoughts About A Pay Rise For Coloplast A/S' (CPH:COLO B) CEO This Year?

Nov 29
Should Shareholders Have Second Thoughts About A Pay Rise For Coloplast A/S' (CPH:COLO B) CEO This Year?

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Nov 13
Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Earnings Update: Coloplast A/S (CPH:COLO B) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Nov 08
Earnings Update: Coloplast A/S (CPH:COLO B) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Oct 18
Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Coloplast A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Aug 23
Coloplast A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Are Investors Undervaluing Coloplast A/S (CPH:COLO B) By 38%?

Aug 22
Are Investors Undervaluing Coloplast A/S (CPH:COLO B) By 38%?

Subdued Growth No Barrier To Coloplast A/S' (CPH:COLO B) Price

Jul 17
Subdued Growth No Barrier To Coloplast A/S' (CPH:COLO B) Price

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Jun 29
These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations

May 21
Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of DKK5.00

May 10
Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of DKK5.00

Analyst Estimates: Here's What Brokers Think Of Coloplast A/S (CPH:COLO B) After Its Interim Report

May 09
Analyst Estimates: Here's What Brokers Think Of Coloplast A/S (CPH:COLO B) After Its Interim Report

A Look At The Fair Value Of Coloplast A/S (CPH:COLO B)

Apr 26
A Look At The Fair Value Of Coloplast A/S (CPH:COLO B)

There's Reason For Concern Over Coloplast A/S' (CPH:COLO B) Price

Apr 08
There's Reason For Concern Over Coloplast A/S' (CPH:COLO B) Price

Is Coloplast (CPH:COLO B) A Risky Investment?

Mar 21
Is Coloplast (CPH:COLO B) A Risky Investment?

Estimating The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Jan 09
Estimating The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Coloplast A/S' (CPH:COLO B) Price Is Out Of Tune With Earnings

Dec 22
Coloplast A/S' (CPH:COLO B) Price Is Out Of Tune With Earnings

Financial Position Analysis

Short Term Liabilities: COLO B's short term assets (DKK10.4B) exceed its short term liabilities (DKK10.2B).

Long Term Liabilities: COLO B's short term assets (DKK10.4B) do not cover its long term liabilities (DKK19.9B).


Debt to Equity History and Analysis

Debt Level: COLO B's net debt to equity ratio (116.2%) is considered high.

Reducing Debt: COLO B's debt to equity ratio has increased from 15.4% to 120.6% over the past 5 years.

Debt Coverage: COLO B's debt is not well covered by operating cash flow (12.8%).

Interest Coverage: COLO B's interest payments on its debt are well covered by EBIT (11.4x coverage).


Balance Sheet


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 09:26
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Coloplast A/S is covered by 49 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Morten LarsenABG Sundal Collier
Kamla SinghAlphaValue
Robert BateBarclays